Completed
Intravitreal Conbercept Injection in Patients With Myopic Choroidal Neovascularization
What is being tested
3+PRN
+ 6+PRN
Drug
Who is being recruted
Eye Diseases+5
+ Metaplasia
+ Neovascularization, Pathologic
Over 18 Years
+14 Eligibility Criteria
How is the trial designed
Treatment Study
Interventional
Study Start: June 2019
Summary
Principal SponsorZhongshan Ophthalmic Center, Sun Yat-sen University
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner
Study start date: June 13, 2019
Actual date on which the first participant was enrolled.Choroidal neovascularization (CNV) secondary to pathologic myopia (PM-CNV) is a common vision-threatening complication and often affects adults of working age. Intravitreal injection of any anti-vascular endothelial growth factor (VEGF) drugs would significantly suppress the activity of the CNV and finally improve the visual acuity. However, more than half of the patients would need one or more further injection for the recurrence or uncontrolled with 1+pro re nata (PRN) treatment within one year, and whether increasing the initial loading of intravitreal injection of anti-VEGF would be more efficacy for the controlling the PM-CNV remained unknown.
Official TitleIntravitreal Conbercept Injection in Patients With Myopic Choroidal Neovascularization
Principal SponsorZhongshan Ophthalmic Center, Sun Yat-sen University
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Design Details
50 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Eye DiseasesMetaplasiaNeovascularization, PathologicPathologic ProcessesPathological Conditions, Signs and SymptomsUveal DiseasesChoroid DiseasesChoroidal Neovascularization
Criteria
6 inclusion criteria required to participate
Patients who are aged ≥18 years, male or female
Active choroidal neovascularization secondary to pathologic myopia, high myopia (defined as spherical equivalent ≤-6.0 diopter, AL≥26mm), presence of posterior changes compatible with pathologic myopia, presence of active leakage from CNV, and presence of intra-retinal or subretinal fluid or increase of central retinal thickness
Presence of at least 1 of the following lesion types: subfoveal, juxtafoveal with involvement of the central macular area, extrafoveal with involvement of the central macular area, margin of the optic disk with involvement of the central macular area
24≤BCVA≤78, at a starting distance of 4 meters using Early Treatment Diabetic Retinopathy Study (ETDRS) like VA chart ( 20/32-20/320 Snellen equivalent)
Show More Criteria
8 exclusion criteria prevent from participating
Pan-retinal or focal/grid laser photocoagulation with involvement of the macular area in the study eye at any time
Intraocular treatment with corticosteroids or intraocular surgery within 3 months prior to randomization and treatment with anti-VEGF or verteporfin photodynamic therapy at any time in the study eye.
Presence of CNV secondary to any cause other than pathologic myopia.
Presence of active infectious disease or intraocular inflammation, active or suspected periocular infection or iris neovascularization in either eye at the time of enrollment.
Show More Criteria
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.Treatment Groups
Study Objectives
2 intervention groups are designated in this study
This study does not include a placebo group
Treatment Groups
Group I
Experimentalpatients were given intravitreal injection of Conbercept 0.5mg every month repeated for 3 months. Thereafter, intravitreal Conbercept 0.5mg injections should be administered in case CNV persisted or recurred (based on the assessment of defined criteria for retreatment) at a maximum frequency of once every 4 weeks through 12 months
Group II
Experimentalpatients were given intravitreal injection of Conbercept 0.5mg every month repeated for 6 months.Thereafter, intravitreal Conbercept 0.5mg injections should be administered in case CNV persisted or recurred (based on the assessment of defined criteria for retreatment) at a maximum frequency of once every 4 weeks through 12 months
Study Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
Suspended
CompletedOne Study Center